STOCK TITAN
  1. Home
  2. Sec-filings
  3. RDY
  4. [6-K] DR REDDYS LABORATORIES LTD Current Report (Foreign Issuer)

Dr. Reddy’s Laboratories (NYSE: RDY) links June 2026 earnings call audio

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories Limited, a foreign private issuer, reports that audio recordings of its earnings call for the quarter ended June 30, 2026 are available online. The earnings call was conducted on July 22, 2026, and a web link has been provided to the listed stock exchanges for information and records.

Positive

  • None.

Negative

  • None.
Quarter end date June 30, 2026 Quarter for which the earnings call audio relates
Earnings call date July 22, 2026 Date on which the earnings call was conducted
NSE stock code DRREDDY Stock code on National Stock Exchange of India Ltd.
BSE stock code 500124 Stock code on BSE Limited
Form 6-K regulatory
"SECURITIES AND EXCHANGE COMMISSION Form 6-K REPORT OF FOREIGN PRIVATE ISSUER"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
foreign private issuer regulatory
"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
Regulation 30 regulatory
"Pursuant to Regulation 30 of the Securities and Exchange Board of India"
Listing Obligations and Disclosure Requirements Regulations, 2015 regulatory
"Listing Obligations and Disclosure Requirements Regulations, 2015, please find below the link"
earnings call financial
"audio recordings of the Earnings call for the quarter ended June 30, 2026"
A scheduled public meeting—usually by phone or webcast—where a company’s executives present recent financial results and answer questions from analysts and investors. It matters because listeners hear both the factual “report card” on past performance and the leaders’ tone and outlook for the future; new details or shifts in confidence can change investor expectations and move the stock price, much like a parent-teacher meeting revealing a student’s progress and plans.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What does Dr. Reddy’s Laboratories (RDY) disclose in this Form 6-K?
Dr. Reddy’s Laboratories discloses that audio recordings of its earnings call for the quarter ended June 30, 2026 are available via a web link shared with multiple stock exchanges.

Which period does the RDY earnings call referenced in the 6-K cover?
The earnings call referenced covers the company’s results for the quarter ended June 30, 2026. The notice simply points to the call’s audio recording for that period.

On what date was Dr. Reddy’s (RDY) earnings call held?
The earnings call was conducted on July 22, 2026. Dr. Reddy’s later circulated the audio link to the National Stock Exchange of India, BSE, NYSE and NSE IFSC on July 23, 2026.

Does the RDY Form 6-K include detailed financial results for the quarter?
The report highlights that an audio recording of the earnings call is available and provides its link. It does not reproduce detailed financial figures within this notice itself.
 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934


July 2026

 

Commission File Number 1-15182

 

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

 

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x                               Form 40-F   ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

 

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

 

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes  ¨                                     No   x

 

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.


 

 

EXHIBITS

 

Exhibit

Number

  

Description of Exhibits

 

 

 

99.1


Intimation dated July 23, 2026

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

DR. REDDY’S LABORATORIES LIMITED

(Registrant)

 

 

 

 

Date: July 23, 2026

By:

/s/ K Randhir Singh

 

 

Name:

K Randhir Singh

 

 

Title:

Company Secretary

 

3

Exhibit 99.1 


Dr. Reddy's Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills

Hyderabad – 500 034, Telangana, India

 

CIN: L85195TG1984PLC004507

 

Tel:     + 91 40 4900 2900

Fax:    + 91 40 4900 2999

Email: mail@drreddys.com

Web: www.drreddys.com

 

July 23, 2026

 

National Stock Exchange of India Ltd. (Stock Code: DRREDDY)

BSE Limited (Stock Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

 

Dear Sir/ Madam,

 

Sub: Audio Recordings of the Earnings call conducted on July 22, 2026

 

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find below the link of the audio recordings of the Earnings call for the quarter ended June 30, 2026, conducted on July 22, 2026.

 

Weblink:https://www.drreddys.com/cms/sites/default/files/2026-07/GMT20260722-140008_Recording%20.mp3

 

This is for your information and records.

 

Thanking you.

 

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases